Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.60
+0.14 (1.65%)
At close: Jan 20, 2026, 4:00 PM EST
8.57
-0.03 (-0.32%)
After-hours: Jan 20, 2026, 4:24 PM EST
Kura Oncology Revenue
Kura Oncology had revenue of $20.75M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $104.03M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$104.03M
Revenue Growth
n/a
P/S Ratio
7.11
Revenue / Employee
$541,818
Employees
192
Market Cap
748.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.88M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
KURA News
- 9 days ago - Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - GlobeNewsWire
- 15 days ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript - Seeking Alpha
- 6 weeks ago - Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - GlobeNewsWire
- 6 weeks ago - Kura Oncology: A Cautious Buy - Seeking Alpha
- 6 weeks ago - Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data - Seeking Alpha
- 7 weeks ago - First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - GlobeNewsWire